Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Philogen SpA ( (IT:PHIL) ) just unveiled an announcement.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,547 shares from September 22 to 26, 2025, at an average price of €22.5250 per share, totaling €34,846.10. Since the program’s inception, Philogen has acquired 30,995 shares, representing 0.0763% of its share capital, with a total value of €692,193.82. This buyback initiative reflects Philogen’s strategic financial management and could potentially enhance shareholder value by reducing the number of outstanding shares.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for treating high-mortality diseases. The company focuses on developing targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through tumor targeting and vascular targeting strategies. Philogen aims to create innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies, drug development expertise, and a broad portfolio of patents.
YTD Price Performance: 21.03%
Average Trading Volume: 16,757
Technical Sentiment Signal: Buy
Current Market Cap: €690.1M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.